Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
NCT03681535 · View on ClinicalTrials.gov ↗
Study Summary
This phase II study will evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity . Hypothesis: The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control in patients who had a negative PET-CT scan following rituximab - containing chemotherapy.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
Study Locations (12)
Other
- University Hospital Motol — Prague
- University of Torino — Torino
- Juntendo University — Tokyo
- National Cancer Center of Singapore — Singapore
- Yonsei University Health System — Seoul
Massachusetts
- Massachusetts General Hospital — Boston
- Dana Farber Cancer Institute — Boston
- Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital — Weymouth
Missouri
- Washington University School of Medicine — St Louis
New York
- University of Rochester James P. Wilmot Cancer Institute — Rochester
North Carolina
- Duke University Medical Center — Durham
Texas
- MD Anderson Cancer Center — Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2019-02-13 |
| Est. Completion | 2028-07 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03681535
The ClinicalTrials.gov registry entry for NCT03681535 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,129 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention — of which Radiation Therapy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03681535 reports 12 study locations spanning 6 distinct geographic areas — top geographies include Other, Massachusetts, Missouri. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03681535 about?
NCT03681535 is a clinical study titled "Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma". This phase II study will evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity . Hypothesis: The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining hi...
What is the current status of trial NCT03681535?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 241 participants. The study started on 2019-02-13. Estimated completion is 2028-07.
What conditions does trial NCT03681535 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03681535?
The interventions under investigation include: Radiation Therapy (RADIATION). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03681535?
This trial is sponsored by Duke University, which has 1,129 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03681535 being conducted?
This trial has 12 study locations across Massachusetts, Missouri, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.